Mechanism

How it works

BPC-157 modulates the nitric oxide system and upregulates growth factor receptors (VEGFR2, EGFR) to promote angiogenesis and tissue repair. GHK-Cu (copper tripeptide) activates over 4,000 genes related to collagen and elastin production, antioxidant defense, and anti-inflammatory signaling via activation of the proteasome and TGF-β pathways. TB-500 (Thymosin Beta-4) sequesters G-actin to regulate actin polymerization, promoting cell migration, differentiation, and vascular repair through upregulation of Thymosin Beta-4 and its downstream effectors including integrin-linked kinase.

Reported in research

Benefits

Accelerated wound healing and tissue repair across skin, muscle, tendon, and connective tissue
Significant improvement in skin texture, elasticity, and collagen density via GHK-Cu-mediated gene activation
Reduction of systemic and local inflammation, supporting recovery from injury, overtraining, and surgery
Enhanced angiogenesis and blood flow to damaged tissues, facilitating nutrient and oxygen delivery for regeneration

Context, not a prescription

Dosing

Typical range: One vial (70mg blend) reconstituted; typical subcutaneous dose of 0.1–0.2mL per injection, 3–5x per week (Subcutaneous, Intramuscular)
Cycle length: 8–12 weeks, with 4–6 week break
Half-life: BPC-157: ~4 hours; GHK-Cu: ~1–2 hours; TB-500: ~days (slow-release kinetics)

Safety

Side effects & contraindications

Possible side effects

Mild injection site redness or irritation
Transient fatigue or lightheadedness post-injection
Potential nausea (primarily associated with BPC-157 at higher doses)
Temporary flushing or warmth near injection site (GHK-Cu copper complex)

Contraindications

Active or history of malignancy (GHK-Cu and BPC-157 upregulate growth factors that may theoretically stimulate tumor proliferation)
Pregnancy or breastfeeding (insufficient safety data)
Known hypersensitivity to any component peptide or copper
Active autoimmune conditions without physician supervision

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Users commonly report softer, more radiant skin, faster recovery from workouts or minor injuries, reduced joint discomfort, improved gut comfort, and an overall sense of physical well-being.

How it works

Think of GLOW like a home renovation team: BPC-157 is the structural engineer fixing the foundation and pipes (organs and gut), TB-500 is the general contractor coordinating all the workers and materials (cell movement and repair), and GHK-Cu is the interior designer refreshing the surfaces and aesthetics (skin, collagen, anti-aging). Each plays a distinct role, but together the house looks and functions far better than any one contractor working alone.

When injected subcutaneously, all three peptides enter the bloodstream and travel to areas of damage or need. GHK-Cu is particularly active in the skin and connective tissues, while BPC-157 has strong effects in the gut lining and tendons, and TB-500 circulates widely to promote broad tissue regeneration. The effects build over time with consistent dosing.

What to expect

Many users notice reduced soreness and improved skin hydration within the first 1–2 weeks. More visible skin and recovery changes typically emerge by weeks 3–6.

Week 1: Injection site reactions may occur; subtle anti-inflammatory effects begin; improved skin hydration may be noticed
Weeks 2–4: Recovery from workouts or minor injuries noticeably faster; skin texture begins to improve; gut comfort may increase
Weeks 4–8: Visible improvements in skin radiance and elasticity; significant reduction in chronic inflammation markers; enhanced overall tissue resilience

Good to know

Always start with a lower test dose (0.1mL) to assess individual tolerance before progressing to full doses
Use bacteriostatic water for reconstitution and maintain cold-chain storage to preserve peptide integrity

Staying safe

Mild redness or a small bump at the injection site that fades within hours
Occasional mild nausea shortly after injection, especially at higher doses

Avoid if you have:

People with a personal or family history of cancer
Pregnant or breastfeeding women
Anyone with a known allergy to peptides or copper

Overview

Histological changes associated with the blend include: increased type I and III collagen fiber density, elevated vascular endothelial density in healing tissue, reduced IL-6 and TNF-α expression, increased Nrf2-mediated antioxidant gene activation, and upregulation of BMP-signaling pathways relevant to bone and cartilage matrix remodeling. Clinically, these translate to measurable improvements in wound tensile strength, dermal thickness via ultrasound, and inflammatory biomarker panels.

How it works

Imagine tissue repair as a three-tier military operation: BPC-157 acts as the logistics commander establishing supply lines (blood vessels via VEGFR2 signaling) and stabilizing the operational environment (NO modulation, gut-brain axis repair); GHK-Cu functions as the intelligence network, activating thousands of downstream genetic programs that determine how cells respond to damage; and TB-500 is the rapid deployment force, mobilizing stem cells and progenitor cells to breach damaged tissue barriers via actin cytoskeletal reorganization.

Following subcutaneous injection, BPC-157 distributes rapidly with a ~4-hour half-life and exhibits preferential bioavailability at mucosal surfaces, tendons, and the gut-brain axis. GHK-Cu has a shorter plasma half-life (~1–2 hours) but demonstrates prolonged local tissue effects through receptor-mediated endocytosis and nuclear translocation, modulating chromatin remodeling. TB-500's actin-binding mechanism creates a sustained depot effect, with Thymosin Beta-4 protein exhibiting a half-life measured in days in some tissue compartments. All three peptides avoid hepatic first-pass metabolism via subcutaneous administration, maximizing bioavailability.

Onset & timeline

Pharmacokinetically, BPC-157 achieves peak plasma concentration within 30–60 minutes post-injection; GHK-Cu receptor occupancy peaks within 1–2 hours with downstream gene expression changes observable within 24–48 hours; TB-500's actin-binding effects begin within hours but cell migration upregulation is measurable at 48–72 hours. Clinically perceptible effects (reduced DOMS, skin changes) typically emerge at 7–14 days of consistent dosing.

Days 1–3: BPC-157 achieves steady-state receptor occupancy; GHK-Cu begins gene activation programs (TGF-β1, MMP-1/2); TB-500 actin-binding reaches equilibrium with G-actin pools
Weeks 1–2: Measurable increases in local VEGF expression and capillary sprouting in target tissues; collagen gene upregulation detectable; reduction in acute-phase inflammatory proteins; improved subjective pain scores in musculoskeletal applications
Weeks 2–8: Sustained collagen I/III remodeling; dermal matrix thickening measurable by 20MHz ultrasound; accelerated tendon/ligament fibril maturation; systemic antioxidant capacity elevated via Nrf2/SOD2 upregulation; peak cosmetic and recovery benefits typically observed at 6–8 weeks

Getting the most from it

Monitor serum copper levels with extended GHK-Cu use, particularly in individuals with hepatic impairment
Conduct baseline and periodic inflammatory marker panels (CRP, IL-6) to assess systemic response
Rotate injection sites to prevent localized lipodystrophy and ensure consistent absorption kinetics

Common side effects

Transient injection-site erythema and induration (<24 hours) due to mild immune recognition of foreign peptides
Vasodilatory effects of BPC-157 (NO-mediated) may cause transient orthostatic hypotension in sensitive individuals
GHK-Cu copper complexation may cause localized warmth or discoloration at high concentrations

Mechanism of action

BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from gastric juice protein BPC that modulates the nitric oxide (NO) system, upregulates VEGFR2 and EGF receptor expression, and activates the FAK-paxillin signaling cascade to accelerate angiogenesis, myotendinous repair, and enteric nervous system healing. GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) binds copper in a square planar configuration and functions as a potent gene regulator, activating genes encoding for collagen I/III, decorin, TGF-β1, matrix metalloproteinases, and superoxide dismutase, while simultaneously suppressing inflammatory NF-κB signaling—documented to regulate over 4,000 human genes in microarray studies. TB-500 (the active fragment of Thymosin Beta-4, Ac-SDKP sequence region) sequesters G-actin via its LKKTET actin-binding domain, promoting lamellipodia formation, endothelial and keratinocyte migration, cardiomyocyte survival, and ILK (integrin-linked kinase)-mediated cell differentiation and survival. The synergy of these three peptides creates overlapping coverage across angiogenesis (all three), collagen remodeling (BPC-157 and GHK-Cu), cell migration (TB-500 and GHK-Cu), and anti-inflammatory cascades (BPC-157 and GHK-Cu).

Following subcutaneous injection, BPC-157 distributes rapidly with a ~4-hour half-life and exhibits preferential bioavailability at mucosal surfaces, tendons, and the gut-brain axis. GHK-Cu has a shorter plasma half-life (~1–2 hours) but demonstrates prolonged local tissue effects through receptor-mediated endocytosis and nuclear translocation, modulating chromatin remodeling. TB-500's actin-binding mechanism creates a sustained depot effect, with Thymosin Beta-4 protein exhibiting a half-life measured in days in some tissue compartments. All three peptides avoid hepatic first-pass metabolism via subcutaneous administration, maximizing bioavailability.

Pharmacodynamics

Pharmacokinetically, BPC-157 achieves peak plasma concentration within 30–60 minutes post-injection; GHK-Cu receptor occupancy peaks within 1–2 hours with downstream gene expression changes observable within 24–48 hours; TB-500's actin-binding effects begin within hours but cell migration upregulation is measurable at 48–72 hours. Clinically perceptible effects (reduced DOMS, skin changes) typically emerge at 7–14 days of consistent dosing.

Histological changes associated with the blend include: increased type I and III collagen fiber density, elevated vascular endothelial density in healing tissue, reduced IL-6 and TNF-α expression, increased Nrf2-mediated antioxidant gene activation, and upregulation of BMP-signaling pathways relevant to bone and cartilage matrix remodeling. Clinically, these translate to measurable improvements in wound tensile strength, dermal thickness via ultrasound, and inflammatory biomarker panels.

Timeline

Days 1–3: BPC-157 achieves steady-state receptor occupancy; GHK-Cu begins gene activation programs (TGF-β1, MMP-1/2); TB-500 actin-binding reaches equilibrium with G-actin pools
Weeks 1–2: Measurable increases in local VEGF expression and capillary sprouting in target tissues; collagen gene upregulation detectable; reduction in acute-phase inflammatory proteins; improved subjective pain scores in musculoskeletal applications
Weeks 2–8: Sustained collagen I/III remodeling; dermal matrix thickening measurable by 20MHz ultrasound; accelerated tendon/ligament fibril maturation; systemic antioxidant capacity elevated via Nrf2/SOD2 upregulation; peak cosmetic and recovery benefits typically observed at 6–8 weeks

Comparisons

GLOW Blend (BPC-157 + GHK-Cu + TB-500) — effectiveness High, safety Good, cost $$$, Medium to use
BPC-157 monotherapy — effectiveness Moderate, safety Good, cost $$, Medium to use
TB-500 monotherapy — effectiveness Moderate, safety Good, cost $$, Medium to use

Adverse effects

Common:

Transient injection-site erythema and induration (<24 hours) due to mild immune recognition of foreign peptides
Vasodilatory effects of BPC-157 (NO-mediated) may cause transient orthostatic hypotension in sensitive individuals
GHK-Cu copper complexation may cause localized warmth or discoloration at high concentrations

Rare:

Theoretical oncogenic risk from chronic growth factor upregulation (VEGF, TGF-β) — no documented human cases but flagged by preclinical pharmacology
Immune sensitization to peptide epitopes with repeated dosing cycles (rare, anecdotal)

Contraindications & risk mitigation

Contraindicated in:

Patients with active neoplasia or a history of hormone-receptor positive cancers, due to growth factor pathway upregulation
Individuals with Wilson's disease or copper metabolism disorders (GHK-Cu component)
Patients on anticoagulant therapy without medical supervision (TB-500 may modestly affect platelet aggregation)

Monitor serum copper levels with extended GHK-Cu use, particularly in individuals with hepatic impairment
Conduct baseline and periodic inflammatory marker panels (CRP, IL-6) to assess systemic response
Rotate injection sites to prevent localized lipodystrophy and ensure consistent absorption kinetics

Qué hace

Users commonly report softer, more radiant skin, faster recovery from workouts or minor injuries, reduced joint discomfort, improved gut comfort, and an overall sense of physical well-being.

Cómo funciona

Think of GLOW like a home renovation team: BPC-157 is the structural engineer fixing the foundation and pipes (organs and gut), TB-500 is the general contractor coordinating all the workers and materials (cell movement and repair), and GHK-Cu is the interior designer refreshing the surfaces and aesthetics (skin, collagen, anti-aging). Each plays a distinct role, but together the house looks and functions far better than any one contractor working alone.

When injected subcutaneously, all three peptides enter the bloodstream and travel to areas of damage or need. GHK-Cu is particularly active in the skin and connective tissues, while BPC-157 has strong effects in the gut lining and tendons, and TB-500 circulates widely to promote broad tissue regeneration. The effects build over time with consistent dosing.

Qué esperar

Many users notice reduced soreness and improved skin hydration within the first 1–2 weeks. More visible skin and recovery changes typically emerge by weeks 3–6.

Week 1: Injection site reactions may occur; subtle anti-inflammatory effects begin; improved skin hydration may be noticed
Weeks 2–4: Recovery from workouts or minor injuries noticeably faster; skin texture begins to improve; gut comfort may increase
Weeks 4–8: Visible improvements in skin radiance and elasticity; significant reduction in chronic inflammation markers; enhanced overall tissue resilience

Bueno saber

Always start with a lower test dose (0.1mL) to assess individual tolerance before progressing to full doses
Use bacteriostatic water for reconstitution and maintain cold-chain storage to preserve peptide integrity

Manteniéndose seguro

Mild redness or a small bump at the injection site that fades within hours
Occasional mild nausea shortly after injection, especially at higher doses

Evitar si tienes:

People with a personal or family history of cancer
Pregnant or breastfeeding women
Anyone with a known allergy to peptides or copper

Descripción general

Histological changes associated with the blend include: increased type I and III collagen fiber density, elevated vascular endothelial density in healing tissue, reduced IL-6 and TNF-α expression, increased Nrf2-mediated antioxidant gene activation, and upregulation of BMP-signaling pathways relevant to bone and cartilage matrix remodeling. Clinically, these translate to measurable improvements in wound tensile strength, dermal thickness via ultrasound, and inflammatory biomarker panels.

Cómo funciona

Imagine tissue repair as a three-tier military operation: BPC-157 acts as the logistics commander establishing supply lines (blood vessels via VEGFR2 signaling) and stabilizing the operational environment (NO modulation, gut-brain axis repair); GHK-Cu functions as the intelligence network, activating thousands of downstream genetic programs that determine how cells respond to damage; and TB-500 is the rapid deployment force, mobilizing stem cells and progenitor cells to breach damaged tissue barriers via actin cytoskeletal reorganization.

Following subcutaneous injection, BPC-157 distributes rapidly with a ~4-hour half-life and exhibits preferential bioavailability at mucosal surfaces, tendons, and the gut-brain axis. GHK-Cu has a shorter plasma half-life (~1–2 hours) but demonstrates prolonged local tissue effects through receptor-mediated endocytosis and nuclear translocation, modulating chromatin remodeling. TB-500's actin-binding mechanism creates a sustained depot effect, with Thymosin Beta-4 protein exhibiting a half-life measured in days in some tissue compartments. All three peptides avoid hepatic first-pass metabolism via subcutaneous administration, maximizing bioavailability.

Inicio y cronología

Pharmacokinetically, BPC-157 achieves peak plasma concentration within 30–60 minutes post-injection; GHK-Cu receptor occupancy peaks within 1–2 hours with downstream gene expression changes observable within 24–48 hours; TB-500's actin-binding effects begin within hours but cell migration upregulation is measurable at 48–72 hours. Clinically perceptible effects (reduced DOMS, skin changes) typically emerge at 7–14 days of consistent dosing.

Days 1–3: BPC-157 achieves steady-state receptor occupancy; GHK-Cu begins gene activation programs (TGF-β1, MMP-1/2); TB-500 actin-binding reaches equilibrium with G-actin pools
Weeks 1–2: Measurable increases in local VEGF expression and capillary sprouting in target tissues; collagen gene upregulation detectable; reduction in acute-phase inflammatory proteins; improved subjective pain scores in musculoskeletal applications
Weeks 2–8: Sustained collagen I/III remodeling; dermal matrix thickening measurable by 20MHz ultrasound; accelerated tendon/ligament fibril maturation; systemic antioxidant capacity elevated via Nrf2/SOD2 upregulation; peak cosmetic and recovery benefits typically observed at 6–8 weeks

Cómo aprovecharlo al máximo

Monitor serum copper levels with extended GHK-Cu use, particularly in individuals with hepatic impairment
Conduct baseline and periodic inflammatory marker panels (CRP, IL-6) to assess systemic response
Rotate injection sites to prevent localized lipodystrophy and ensure consistent absorption kinetics

Efectos secundarios comunes

Transient injection-site erythema and induration (<24 hours) due to mild immune recognition of foreign peptides
Vasodilatory effects of BPC-157 (NO-mediated) may cause transient orthostatic hypotension in sensitive individuals
GHK-Cu copper complexation may cause localized warmth or discoloration at high concentrations

Mecanismo de acción

BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from gastric juice protein BPC that modulates the nitric oxide (NO) system, upregulates VEGFR2 and EGF receptor expression, and activates the FAK-paxillin signaling cascade to accelerate angiogenesis, myotendinous repair, and enteric nervous system healing. GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) binds copper in a square planar configuration and functions as a potent gene regulator, activating genes encoding for collagen I/III, decorin, TGF-β1, matrix metalloproteinases, and superoxide dismutase, while simultaneously suppressing inflammatory NF-κB signaling—documented to regulate over 4,000 human genes in microarray studies. TB-500 (the active fragment of Thymosin Beta-4, Ac-SDKP sequence region) sequesters G-actin via its LKKTET actin-binding domain, promoting lamellipodia formation, endothelial and keratinocyte migration, cardiomyocyte survival, and ILK (integrin-linked kinase)-mediated cell differentiation and survival. The synergy of these three peptides creates overlapping coverage across angiogenesis (all three), collagen remodeling (BPC-157 and GHK-Cu), cell migration (TB-500 and GHK-Cu), and anti-inflammatory cascades (BPC-157 and GHK-Cu).

Following subcutaneous injection, BPC-157 distributes rapidly with a ~4-hour half-life and exhibits preferential bioavailability at mucosal surfaces, tendons, and the gut-brain axis. GHK-Cu has a shorter plasma half-life (~1–2 hours) but demonstrates prolonged local tissue effects through receptor-mediated endocytosis and nuclear translocation, modulating chromatin remodeling. TB-500's actin-binding mechanism creates a sustained depot effect, with Thymosin Beta-4 protein exhibiting a half-life measured in days in some tissue compartments. All three peptides avoid hepatic first-pass metabolism via subcutaneous administration, maximizing bioavailability.

Farmacodinamia

Pharmacokinetically, BPC-157 achieves peak plasma concentration within 30–60 minutes post-injection; GHK-Cu receptor occupancy peaks within 1–2 hours with downstream gene expression changes observable within 24–48 hours; TB-500's actin-binding effects begin within hours but cell migration upregulation is measurable at 48–72 hours. Clinically perceptible effects (reduced DOMS, skin changes) typically emerge at 7–14 days of consistent dosing.

Histological changes associated with the blend include: increased type I and III collagen fiber density, elevated vascular endothelial density in healing tissue, reduced IL-6 and TNF-α expression, increased Nrf2-mediated antioxidant gene activation, and upregulation of BMP-signaling pathways relevant to bone and cartilage matrix remodeling. Clinically, these translate to measurable improvements in wound tensile strength, dermal thickness via ultrasound, and inflammatory biomarker panels.

Cronología

Days 1–3: BPC-157 achieves steady-state receptor occupancy; GHK-Cu begins gene activation programs (TGF-β1, MMP-1/2); TB-500 actin-binding reaches equilibrium with G-actin pools
Weeks 1–2: Measurable increases in local VEGF expression and capillary sprouting in target tissues; collagen gene upregulation detectable; reduction in acute-phase inflammatory proteins; improved subjective pain scores in musculoskeletal applications
Weeks 2–8: Sustained collagen I/III remodeling; dermal matrix thickening measurable by 20MHz ultrasound; accelerated tendon/ligament fibril maturation; systemic antioxidant capacity elevated via Nrf2/SOD2 upregulation; peak cosmetic and recovery benefits typically observed at 6–8 weeks

Comparaciones

GLOW Blend (BPC-157 + GHK-Cu + TB-500) — efectividad High, seguridad Good, costo $$$, Medium de usar
BPC-157 monotherapy — efectividad Moderate, seguridad Good, costo $$, Medium de usar
TB-500 monotherapy — efectividad Moderate, seguridad Good, costo $$, Medium de usar

Efectos adversos

Comunes:

Transient injection-site erythema and induration (<24 hours) due to mild immune recognition of foreign peptides
Vasodilatory effects of BPC-157 (NO-mediated) may cause transient orthostatic hypotension in sensitive individuals
GHK-Cu copper complexation may cause localized warmth or discoloration at high concentrations

Raros:

Theoretical oncogenic risk from chronic growth factor upregulation (VEGF, TGF-β) — no documented human cases but flagged by preclinical pharmacology
Immune sensitization to peptide epitopes with repeated dosing cycles (rare, anecdotal)

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients with active neoplasia or a history of hormone-receptor positive cancers, due to growth factor pathway upregulation
Individuals with Wilson's disease or copper metabolism disorders (GHK-Cu component)
Patients on anticoagulant therapy without medical supervision (TB-500 may modestly affect platelet aggregation)

Monitor serum copper levels with extended GHK-Cu use, particularly in individuals with hepatic impairment
Conduct baseline and periodic inflammatory marker panels (CRP, IL-6) to assess systemic response
Rotate injection sites to prevent localized lipodystrophy and ensure consistent absorption kinetics

Reference data

Specifications

Molecular formula: Blend (C62H98N16O22 / C14H23CuN6O4 / C212H350N56O78S): N/A as single formula
Molecular weight: BPC-157: ~1419.5 Da; GHK-Cu: ~403.9 Da; TB-500 (TB4 fragment): ~2888.2 Da
Half-life: BPC-157: ~4 hours; GHK-Cu: ~1–2 hours; TB-500: ~days (slow-release kinetics)
Route: Subcutaneous, Intramuscular
Cycle length: 8–12 weeks, with 4–6 week break
Storage: Lyophilized powder: store at -20°C to 4°C, away from light and moisture. After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28–30 days. Do not freeze reconstituted solution.
Legal status: Research chemical only in most jurisdictions; not FDA-approved for human use. Legal to purchase for research purposes in the US, Canada, and Australia. Not permitted for sale as a therapeutic agent.

FAQ

Common questions

Is there synergistic evidence for combining all three peptides in a single formulation?

Direct head-to-head combination studies are currently absent from peer-reviewed literature. The synergy rationale is mechanistically driven: BPC-157 and TB-500 cover overlapping angiogenic and cell-migration pathways (VEGF, ILK), while GHK-Cu's broad gene regulation (~4,000 genes per Pickart & Margolina 2015) theoretically amplifies the transcriptional response to the tissue microenvironment changes induced by the other two peptides. This remains a hypothesis supported by mechanistic reasoning rather than controlled clinical trials.

What is the pharmacokinetic rationale for the GHK-Cu dose being 5x higher than BPC-157 and TB-500?

GHK-Cu has a significantly shorter plasma half-life (~1–2 hours) and lower receptor affinity compared to BPC-157's direct receptor agonism. The higher molar dose (50mg vs 10mg) compensates for rapid clearance and ensures sufficient copper-peptide complex availability for receptor-mediated endocytosis and nuclear gene activation. BPC-157 and TB-500 operate via higher-affinity receptor interactions that require lower absolute molar doses for equivalent biological effect.

What is the evidence level?

This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Research

Research & sources

Animal data

Current evidence for GLOW (BPC-157 + GHK-Cu + TB-500 Blend) is rated as Animal data. Research is based primarily on animal models.

1. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (2016) — Current Pharmaceutical Design, Sikiric et al., PMID: 27138887
2. Human skin remodeling peptide GHK-Cu and skin gene regulation (2015) — Oxidative Medicine and Cellular Longevity, Pickart L & Margolina A, DOI: 10.1155/2015/648108
3. Thymosin beta4 and its role in wound healing and tissue repair (2010) — Annals of the New York Academy of Sciences, Goldstein AL & Kleinman HK, DOI: 10.1111/j.1749-6632.2009.05375.x
4. The actin-sequestering protein thymosin-β4 promotes angiogenesis, wound healing, and tissue regeneration (2005) — FASEB Journal, Bock-Marquette I et al., DOI: 10.1096/fj.04-3134fje

Explore

Often discussed alongside

BPC-157 · healing TB-500 · healing GHK-Cu · skin Ipamorelin · growth CJC-1295 · growth